Global Erythropoietin Stimulating Agents Market Growth (Status and Outlook) 2025-2031

According to this study, the global Erythropoietin Stimulating Agents market size will reach US$ 13310 million by 2031.

Erythropoiesis-stimulating agents (ESA) are medications which stimulate the bone marrow to make red blood cells. They are used to treat anemia due to end stage kidney disease, chemotherapy, major surgery, or certain treatments in HIV/AIDS.

United States market for Erythropoietin Stimulating Agents is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for Erythropoietin Stimulating Agents is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for Erythropoietin Stimulating Agents is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key Erythropoietin Stimulating Agents players cover Pfizer, Amgen, BioSidus, Biocon, Celltrion, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LPI (LP Information)' newest research report, the “Erythropoietin Stimulating Agents Industry Forecast” looks at past sales and reviews total world Erythropoietin Stimulating Agents sales in 2024, providing a comprehensive analysis by region and market sector of projected Erythropoietin Stimulating Agents sales for 2025 through 2031. With Erythropoietin Stimulating Agents sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Erythropoietin Stimulating Agents industry.

This Insight Report provides a comprehensive analysis of the global Erythropoietin Stimulating Agents landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Erythropoietin Stimulating Agents portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Erythropoietin Stimulating Agents market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Erythropoietin Stimulating Agents and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Erythropoietin Stimulating Agents.

This report presents a comprehensive overview, market shares, and growth opportunities of Erythropoietin Stimulating Agents market by product type, application, key players and key regions and countries.

Segmentation by Type:
Epoetin Alfa
Epoetin Beta
Darbepoetin Alfa
Others

Segmentation by Application:
Hospitals
Clinics
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Pfizer
Amgen
BioSidus
Biocon
Celltrion
Roche
Intas Pharmaceuticals
Johnson & Johnson
Teva Pharmaceutical Industries
Thermo Fisher Scientific

Please note: The report will take approximately 2 business days to prepare and deliver. Show more